Arena (ARNA) Rivals Mixed Ahead of PDUFA; Volatility Elevated (OREX) (VVUS)
Tweet
Share
E-mailGet Alerts ARNA Hot Sheet
Join SI Premium – FREE
Ahead of Arena Pharmaceuticals' (Nasdaq: ARNA) PDUFA meeting for proposed weight-loss drug lorcaserin today, rivals are looking mixed.
Pre-market action shows VIVUS (Nasdaq: VVUS) lower while Orexigen (Nasdaq: OREX) is looking about 2.7 percent stronger early.
VIVUS has an FDA meeting in July for its obesity drug Qnexa, while Orexigen is looking for approval of its Contrave drug.
Arena shares more than doubled following a positive FDA panel call on May 10th, while VIVUS and Orexigen have seen similar gains.
Volatility for Orexigen has been above its trailing annual average since April while VIVUS volatility has slowly increased since May.
Pre-market action shows VIVUS (Nasdaq: VVUS) lower while Orexigen (Nasdaq: OREX) is looking about 2.7 percent stronger early.
VIVUS has an FDA meeting in July for its obesity drug Qnexa, while Orexigen is looking for approval of its Contrave drug.
Arena shares more than doubled following a positive FDA panel call on May 10th, while VIVUS and Orexigen have seen similar gains.
Volatility for Orexigen has been above its trailing annual average since April while VIVUS volatility has slowly increased since May.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BJ's Wholesale Club (BJ) call put ratio 1.3 calls to 1 put into quarter results
- Ross Stores (ROST) 9K contracts of September 220 puts trade into quarter results
Create E-mail Alert Related Categories
Insiders' Blog, Momentum Movers, OptionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
